Healthy Subjects
Conditions
Keywords
Bioequivalence, Randomized, Crossover, Etoricoxib
Brief summary
To evaluate and compare the relative plasma bioavailability and therefore the bioequivalence of two different immediate release products each containing Etoricoxib 90 mg, after administering a single oral dose, to healthy adult subjects under fasting conditions.
Detailed description
Enrolled subjects were randomized in a two-phase, two-sequence, cross-over design to receive a single dose of the test product (T) or the reference product (R) at each phase, under fasting conditions, with a wash-out period of 14 days. Etoricoxib plasma concentration was determined using a validated LC-MS-MS method, followed by Pharmacokinetics, and statistical analysis using Phoenix WinNonlin® software to determine the average bioequivalence.
Interventions
DRUGEtoricoxib 90 mg film coated tablet
an immediate-release tablet containing 90 mg of Etoricoxib
DRUGArcoxia 90 mg film coated tablet
an immediate-release tablet containing 90 mg of Etoricoxib
Sponsors
Future University in Egypt
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Intervention model description
A randomized, single-dose, two-way crossover, open-label, laboratory blind, bioequivalence study
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Written informed consent is obtained for the study. * Age 18 - 55 years, * Body mass index between 18.5 and 30 kg/m2 * Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination. * Vital signs without significant deviations. * All laboratory screening results are within the normal range or clinically non-significant
Exclusion criteria
* History or presence of any disorder or condition that would render the subject unsuitable for the study, place the subject at undue risk, or interfere with the ability of the subject to complete the study in the investigator's opinion. * History of significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, allergic, dermatologic, hematologic, neurologic, psychiatric disease, or cancer. * Any confirmed significant allergic reactions against any drug or multiple allergies. * Clinically significant illness 28 days before study phase I. * Alcohol or any solvent intake. * Regular use of medication. * Positive urine screening of drugs of abuse. * Use of any systemic medications (prescription medications, OTC products, supplements, or herbal preparations) for 14 days prior to dosing and during the study. * History or presence of significant smoking (more than one pack per day of cigarettes) or refusal to abstain from smoking for 48 hours before dosing until checkout. * Blood donation within the past 60 days. * Participation in another bioequivalence study within 60 days prior to the start of phase I of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration (Cmax) | (Pre-dose) and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75. 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours | Cmax is observed at the maximum of Etoricoxib peak concentration |
| the area under the curve (AUC 0-t) | (Pre-dose) and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75. 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours | Cumulative Area Under the Etoricoxib plasma concentration-time Curve calculated from 0 to time of last quantifiable concentration (t last) using the Trapezoidal method |
| the area under the curve extrapolated to infinity (AUC0-∞) | (Pre-dose) and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75. 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours | AUC from Dosing time extrapolated to infinity, based on the last observed concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum time (Tmax) | (Pre-dose) and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75. 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours | Time until Cmax is reached |
| Apparent terminal half-life (t½) | (Pre-dose) and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75. 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours | the time required for the Etoricoxib plasma concentration to decrease by 50% after the pseudo-equilibrium of distribution has been reached |
| Apparent elimination rate constant (Kel). | (Pre-dose) and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75. 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours | First-order rate constant associated with the terminal (log-linear) portion of the curve |
Countries
Egypt
Outcome results
None listed